MGMT promoter methylation status is prognostic in IDH1/2wt glioblastoma

MGMT promoter methylation may be prognostic in patients with IDH1/2wt anaplastic glioma, according to an analysis of data from a phase 3 trial conducted by the European Organization for the Treatment of Cancer (EORTC).

Dr Mircea Tesileanu of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, presented the findings at SNO 2020. The trial, known as CATNON, compared radiation therapy plus temozolomide to radiation therapy alone in patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma.